Navigation Links
University of Lodz Invests in the Unique Cellaxess(R)HT System for Research on Multidrug Resistance Genes in Cancer

GOTHENBURG, Sweden, July 22 /PRNewswire/ -- Cellectricon, a leading provider of cell-based screening solutions for research and drug discovery, today announced its collaboration with University of Lodz, Poland. Under the agreement University of Lodz invests in Cellaxess(R)HT, the world's first system for high throughput transfection enabling reagent-free delivery of any genetic material to cells.

To view the Multimedia News Release, please click:

"We are excited about the collaboration with Cellectricon and believe the Cellaxess(R)HT system will greatly advance our efforts in our research program focusing on cell biology and molecular genetics of clinically relevant genes related to cancer treatment," says Prof. Grzegorz Bartosz, head of Department of Molecular Biophysics at the University of Lodz. "Genomic screening is a rapidly-evolving field and the need is very significant for a technology enabling high transfection efficiency and viability in biologically relevant cell types. Cellaxess(R)HT will allow us to undertake ambitious expression and silencing screening projects that would have been both economically and practically unfeasible with conventional instrumentation." Purchase of the Cellaxess(R)HT system by the University of Lodz was made possible by funding from the Innovative Economy Operational Programme of the Republic of Poland, supported in part by the European Union through the European Regional Development Fund.

"Adoption of Cellaxess(R)HT by the University of Lodz into their research program demonstrates the capabilities of this state-of-the-art system designed for genomic research and screening. Cellectricon has developed the system in close collaboration with leading research groups and leading pharmaceutical companies to meet the increasing demand for a generic technology capable of true high throughput transfection," says Jonas Ohlsson, CEO at Cellectricon. "Cellaxess(R)HT will significantly impact this research field since it enables reagent-free high throughput delivery of any genetic material to biologically relevant cell types."

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in preclinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput transfection in genomic screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

    Contact Details:
    Jonas Ohlsson, CEO
    Phone: +46(0)709-73-47-92, E-mail:

    Susanne Fagerlund, VP Marketing & Communications
    Phone: +46(0)31-760-35-15, E-mail:

SOURCE Cellectricon AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
3. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
6. University of Leicester scientists discover technique to help friendly bacteria
7. MichBio Announces Student Career Day at Michigan State University
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
10. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
11. McGill University Purchases GenVaults Personal Archive System to Manage Rare Cancer Samples
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... on behalf of the Toronto Stock Exchange, confirms that ... are no corporate developments that would cause the recent ... --> --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical ...
(Date:11/24/2015)... ... ... This fall, global software solutions leader SAP and AdVenture Capital brought together dozens ... BIG ideas to improve health and wellness in their schools. , Now, the top ... of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, and an ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
Breaking Biology Technology:
(Date:11/19/2015)... , Nov. 19, 2015  Based on its ... & Sullivan recognizes BIO-key with the 2015 Global Frost ... year, Frost & Sullivan presents this award to the ... catering to the needs of the market it serves. ... line meets and expands on customer base demands, the ...
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
Breaking Biology News(10 mins):